China International Capital Corporation Limited (CICC)-backed biopharma firm Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd has kicked off the subscription exercise for its initial public offering (IPO) targeting to raise 1.7 billion yuan ($248 million) on the Nasdaq-style STAR Market of the Shanghai Stock Exchange (SSE), according to a company filing.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
